Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: Molecular and cellular mechanisms of inhibition

Molecular Pharmacology

Volumn 73, Issue 6, 2008, Pages 1761-1768

  Ragunathan, Nilusha ^a   Dairou, Julien ^a   Pluvinage, Benjamin ^a   Martins, Marta ^a   Petit, Emile ^a   Janel, Nathalie ^a   Dupret, Jean Marie ^a   Rodrigues Lima, Fernando ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; CISPLATIN; CYSTEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; ISOENZYMES; MICE; TUMOR CELLS, CULTURED; XENOBIOTICS;

EID: 44249120547     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045328     Document Type: Article

References (40)

1. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, et al. (2003) Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1:826-835.
2. Atmane N, Dairou J, Paul A, Dupret JM, and Rodrigues-Lima F (2003) Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide. J Biol Chem 278:35086-35092.
3. Badawi AF, Hirvonen A, Bell DA, Lang NP, and Kadlubar FF (1995) Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55:5230-5237.
4. Biéche I, Girault I, Urbain E, Tozlu S, and Lidereau R (2004) Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 6:R252-R263.
5. Boubakari, Bracht K, Neumann C, Grunert R, and Bednarski PJ (2004) No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes. Arch Pharm (Weinheim) 337:668-671.
6. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, and Minchin RF (2007) Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Res 67:85-92.
7. Cullen KJ, Yang Z, Schumaker L, and Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39:43-50.
8. Dabrowiak JC, Goodisman J, and Souid AK (2002) Kinetic study of the reaction of cisplatin with thiols. Drug Metab Dispos 30:1378-1384.
9. Dairou J, Atmane N, Dupret JM, and Rodrigues-Lima F (2003) Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols. Biochem Biophys Res Commun 307:1059-1065.
10. Dairou J, Atmane N, Rodrigues-Lima F, and Dupret JM (2004) Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells. A cellular and mechanistic study. J Biol Chem 279:7708-7714.
11. Dairou J, Dupret JM, and Rodrigues-Lima F (2005a) Impairment of the activity of the xenobiotic-metabolizing enzymes arylamine N-acetyltransferases 1 and 2 (NAT1/NAT2) by peroxynitrite in mouse skeletal muscle cells. FEBS Lett 579:4719-4723.
12. Dairou J, Malecaze F, Dupret JM, and Rodrigues-Lima F (2005b) The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases (NAT) in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol 67:1299-1306.
13. Duman RK, Heath RT, and Bose RN (1999) Inhibition of Escherichia coli DNA polymerase-I by the anti-cancer drug cis- diaminedichloroplatinum(II): what roles do polymerases play in cis-platin-induced cytotoxicity? FEBS Lett 455:49-54.
14. Dupret JM and Rodrigues-Lima F (2005) Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr Med Chem 12:311-318.
15. Dwivedi C, Abu-Ghazaleh A, and Guenther J (1996) Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity. Anticancer Drugs 7:792-794.
16. Grant DM, Blum M, Beer M, and Meyer UA (1991) Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-191.
17. Hagrman D, Goodisman J, Dabrowiak JC, and Souid AK (2003) Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 31:916-923.
18. Hagrman D, Goodisman J, and Souid AK (2004) Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 308:658-666.
19. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, et al. (2005) Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 67:937-947.
20. Hein D (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507:65-77.
21. Hein DW (2006) N-Acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:1649-1658.
22. Husain A, Zhang X, Doll MA, States JC, Barker DF, and Hein DW (2007) Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35:721-727.
23. Jestin JL, Lambert B, and Chottard JC (1998) Kinetic study of DNA binding of cisplatin and of a bicycloalkyl-substituted(ethylenediamine) dichloroplatinum(II) complex. J Biol Inorg Chem 3:515-519.
24. Khynriam D and Prasad SB (2002) Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol Toxicol 18:349-358.
25. Korst AE, Boven E, van der Sterre ML, Fichtinger-Schepman AM, and van der Vijgh WJ (1998) Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. Eur J Cancer 34:412-416.
26. Lee JH, Lu HF, Wang DY, Chen DR, Su CC, Chen YS, Yang JH, and Chung JG (2004) Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells. Res Commun Mol Pathol Pharmacol 115-116:217-233.
27. McIlwain CC, Townsend DM, and Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639-1648.
28. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, and Batra SK (2007) Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120:160-169.
29. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, and Butcher NJ (2007) Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 39:1999-2005.
30. Ott I and Gust R (2007) Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 7:95-110.
31. Rodrigues-Lima F, Cooper R, Goudeau B, Atmane N, Chamagne A, Butler-Browne G, Sim E, Vicart P, and Dupret J (2003) Skeletal muscles express the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase. J Histochem Cytochem 51:789-796.
32. Sadzuka Y, Shimizu Y, and Takino Y (1994) Role of glutathione S-transferase isoenzymes in cisplatin-induced nephrotoxicity in the rat. Toxicol Lett 70:211-222.
33. Sfikakis PP, Souliotis VL, Katsilambros N, Markakis K, Vaiopoulos G, Tsokos GC, and Panayiotidis P (1996) Downregulation of interleukin-2 and alpha-chain interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. Clin Immunol Immunopathol 79:43-49.
34. Shin JN, Seo YW, Kim M, Park SY, Lee MJ, Lee BR, Oh JW, Seol DW, and Kim TH (2005) Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J Biol Chem 280:10509-10515.
35. Sim E, Westwood I, and Fullam E (2007) Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol 3:169-184.
36. Sinclair JC, Delgoda R, Noble ME, Jarmin S, Goh NK, and Sim E (1998) Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expr Purif 12:371-380.
37. Tegeder I, Brautigam L, Seegel M, Al-Dam A, Turowski B, Geisslinger G, and Kovacs AF (2003) Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 73:417-426.
38. Townsend DM, Shen H, Staros AL, Gate L, and Tew KD (2002) Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 1:1089-1095.
39. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, and Viale G (2005) Breast cancer. Lancet 365:1727-1741.
40. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC, and Sim E (2008) Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 47:118-126.